Search company, investor...

Founded Year

2003

Stage

Series D | Alive

Total Raised

$92.47M

Last Raised

$13.03M | 5 yrs ago

About Iconic Therapeutics

Iconic Therapeutics is a company focused on the development of new therapeutics in the healthcare and biotechnology industry. The company's main offerings include treatments for acute and chronic inflammatory conditions, serious diseases in ophthalmology, and oncogenic processes that lead to the development and progression of tumors. Iconic Therapeutics primarily serves the healthcare industry. It was founded in 2003 and is based in South San Francisco, California.

Headquarters Location

701 Gateway Blvd Suite 100

South San Francisco, California, 94080,

United States

650-437-1000

Loading...

Loading...

Iconic Therapeutics Patents

Iconic Therapeutics has filed 9 patents.

The 3 most popular patent topics include:

  • coagulation system
  • experimental cancer drugs
  • g protein coupled receptors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/26/2021

9/20/2022

Monoclonal antibodies, Experimental cancer drugs, Clusters of differentiation, Coagulation system, G protein coupled receptors

Grant

Application Date

8/26/2021

Grant Date

9/20/2022

Title

Related Topics

Monoclonal antibodies, Experimental cancer drugs, Clusters of differentiation, Coagulation system, G protein coupled receptors

Status

Grant

Latest Iconic Therapeutics News

Endpoint Health Unveils Precision Immunology Program to Address Tissue Factor-Mediated Inflammation in Autoimmune Diseases

Oct 4, 2022

IND Filing for First-In-Class Clinical Candidate Targeted for 2023 October 04, 2022 08:07 AM Eastern Daylight Time PALO ALTO, Calif.--( BUSINESS WIRE )--Endpoint Health, Inc., a Precision-FirstTM therapeutics company, today unveiled its newest precision immunology program targeting inflammation mediated by tissue factor (TF)-dependent intracellular signaling. The company will leverage its precision AI platform to identify potential responders to the program’s lead asset, EP004, a first-in-class anti-TF monoclonal antibody (mAb), across multiple autoimmune indications. Developing this first-in-class therapy with an innovative precision AI platform across a wide range of indications could potentially transform the treatment paradigm for patients with immune-mediated inflammatory diseases (IMIDs). Rather than using traditional “one-size-fits-all” therapies, this novel precision medicine strategy could enable health care providers to design a treatment plan optimized for each patient’s unique biology. Tissue factor has been a historically under-exploited central biological target and is a fundamental mediator of innate immune activity and coagulation. It is a driver of inflammation, chemotaxis, and hemostasis across a broad range of IMIDs, including ulcerative colitis, Crohn’s disease, lupus, and certain vasculitides. Tissue factor represents an attractive target for disease modifying therapies designed to decrease pro-inflammatory cytokines and chemokines. EP004 (formerly ICON-4) is a first-in-class anti-TF mAb that is uniquely designed to reduce inflammation by selectively inhibiting TF-dependent intracellular signaling, while avoiding interaction with hemostasis-related functions of the TF pathway. EP004 is currently completing IND-enabling studies, and the company expects an IND submission in 2023. This newly unveiled precision immunology program was made possible by Endpoint Health’s recent acquisition of Iconic Therapeutics, a preclinical-stage biotech company developing selective therapies including ICON4 (now EP004) to address TF-mediated signaling. "Using our precision AI platform, we could see the great potential for tissue factor, not only as a therapeutic target, but as an opportunity to develop a highly differentiated precision therapy across a wide range of indications where patients have significant unmet medical need. The opportunity to bring the incredible work of the Iconic Therapeutics team into the clinic for autoimmune diseases represents a key step towards our mission of getting the best therapy to each patient, based on their specific biological need," said Jason Springs, CEO and Co-Founder of Endpoint Health. "As an investor, drug developer and CEO, I’ve seen how precision approaches to drug development have transformed oncology and genetically defined diseases. We’re at the cusp of a similar revolution in immunology where there is a huge need for both new therapies and a better way to target them to the right patient. Combining our novel pipeline with Endpoint Health’s unique precision capability is a rare opportunity to solve for both needs," said Bill Greene, CEO of Iconic Therapeutics. This new program unveiling closely follows Endpoint Health’s appointment of Ransi Somaratne as Chief Medical Officer and a Series A financing round of $52 million, which closed earlier this year with commitments from major institutional investors, such as Mayfield, Humboldt Fund, AME Cloud Ventures, Global Health Investment Corporation (GHIC), and others. About Endpoint Health Endpoint Health is a Precision-FirstTM therapeutics company dedicated to addressing unmet needs in immune-mediated chronic and acute diseases. We leverage our proprietary artificial intelligence (AI) platform and combine companion diagnostics with therapeutics to develop precision therapies. Our vision is a world in which all patients get the best treatment possible for their unique biology and disease. For more information, visit www.endpointhealth.com . Follow us on Social Media: LinkedIn , Twitter About Iconic Therapeutics Iconic Therapeutics, incorporated in 2002, a wholly owned subsidiary of Endpoint Health, developed a portfolio of proprietary molecules that bind to and antagonize TF-mediated signaling. Their unique approach to modulating TF-mediated regulation of multiple cytokines and chemokines without undue interference in coagulation (another cascade mediated by TF) creates the potential for a new class of biopharmaceuticals for improved treatment of serious diseases. In 2020, Exelixis, Inc. exercised their rights under a May 2019 option & license agreement with Iconic for their ICON-2 asset, a TF-targeting antibody drug conjugate, with potential broad impact in oncology. Exelixis has since moved the molecule (now known as XB002) into a large, Phase I clinical trial enrolling patients with advanced solid tumors ( ClinicalTrials.gov NCT04925284). Contacts

Iconic Therapeutics Frequently Asked Questions (FAQ)

  • When was Iconic Therapeutics founded?

    Iconic Therapeutics was founded in 2003.

  • Where is Iconic Therapeutics's headquarters?

    Iconic Therapeutics's headquarters is located at 701 Gateway Blvd, South San Francisco.

  • What is Iconic Therapeutics's latest funding round?

    Iconic Therapeutics's latest funding round is Series D.

  • How much did Iconic Therapeutics raise?

    Iconic Therapeutics raised a total of $92.47M.

  • Who are the investors of Iconic Therapeutics?

    Investors of Iconic Therapeutics include MPM Capital, H.I.G. BioHealth Partners, Lundbeckfond Ventures, HBM Healthcare Investments, Osage University Partners and 9 more.

  • Who are Iconic Therapeutics's competitors?

    Competitors of Iconic Therapeutics include AM-Pharma, Array Biopharma, Threshold Pharmaceuticals, ActoGeniX, Decimmune Therapeutics and 7 more.

Loading...

Compare Iconic Therapeutics to Competitors

REGiMMUNE Logo
REGiMMUNE

REGiMMUNE is a biotechnology company focused on the development of novel medicines for immune disorders. The company's main offerings include treatments designed to modulate the immune system and harness a patient's own immune response for inducing tolerance and achieving anti-tumor effects. These therapies are aimed at a range of immune-related conditions. It was founded in 2006 and is based in Tokyo, Japan.

S
SpiderBiotech S.r.l.

Spider Biotech is a young and dynamic biotechnology company founded in 2005 with the aim of developing synthetic peptide therapeutics. nnAntimicrobial host-defense peptides have been recognized as an important part of innate immunity found throughout the evolutionary tree that defend against invading bacteria, viruses, and fungi through membrane or metabolic disruption. Inspired by natural antimicrobial peptides, Spider Biotech is developing a library of bioactive peptides and lipopeptides active against bacterial and viral infections. nSpiderBiotech's business strategy is to remain focused on the discovery and early-stage development of drug candidates and seek to establish partnerships with pharmaceutical companies for late-stage development and commercialization of its products. nnThe firm aims to become leader in developing peptide-based antiinfectives to address the urgent and global problem posed by resistance to conventional treatments. The Company is headquartered at the Bioindustry Park del Canavese (Turin, Italy).

D
Dare Bioscience

Dare Bioscience operates a healthcare company. Its commitment is to develop and commercialize innovative products in women's reproductive health. Dare Bioscience was formerly known as Tempo Pharmaceuticals. The company was founded in 2005 and is based in San Diego, California.

I
Inflazyme Pharmaceuticals

Juli4D is an online lottery platform specializing in providing access to major Asian lottery markets, particularly in the online gambling industry. The company offers services that allow users to bet on lottery numbers, track lottery results, and manage their gambling accounts. Juli4D is recognized for its partnerships with Toto SGP and Toto HK, offering a trusted platform for lottery enthusiasts. It was founded in 1992 and is based in Richmond, British Columbia.

E
Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

T
TargAnox

TargAnox offers therapeutics to treat diseases resulting from oxidative stress-induced protein aging

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.